ANPA-0073
Pulmonary Arterial Hypertension (PAH)
Key Facts
About Structure Therapeutics
Structure Therapeutics is pioneering the development of next-generation oral small molecule medicines targeting G protein-coupled receptors (GPCRs), a historically challenging but highly validated class of drug targets. The company's lead asset, GSBR-1290, is a highly selective oral GLP-1 receptor agonist in Phase 2 development for obesity and type 2 diabetes, aiming to compete with injectable GLP-1 therapies. With a strong pipeline of preclinical candidates for other cardiometabolic and pulmonary conditions, Structure is positioned at the forefront of the oral incretin market. The company's strategy is built on its integrated computational and experimental platform to design differentiated therapeutics with improved patient convenience and adherence.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension (PAH) Drugs
| Drug | Company | Phase |
|---|---|---|
| YUTREPIA™ (treprostinil) inhalation powder | Liquidia Corporation | Approved (Tentative) |
| LIQ861 (treprostinil) inhalation powder | Liquidia Corporation | Phase 3 |
| KER-012 | Keros Therapeutics | Phase 2 |
| CS1 | Cereno Scientific | Phase II |
| Seralutinib | Gossamer Bio | Phase 3 |
| NTP42 | ATXA Therapeutics | Phase 1 |